Innovating Works

BIOS

Desconocido
T2EVOLVE: Accelerating Development and Improving Access to CAR and TCR engineered T cell therapy BIOSCI CONSULTING BVBA participó en un H2020 H2020-JTI-IMI2-2019-18-two-stage Immune cells that are empowered by gene-engineering to seek and destroy cancer cells (engineered T cell therapy) constitute a transformative...
2020-11-24 - 2025-12-31 | Financiado
DRAGON: The RapiD and SecuRe AI enhAnced DiaGnosis Precision Medicine and Patient EmpOwerment Centered Deci... BIOSCI CONSULTING BVBA participó en un H2020 H2020-JTI-IMI2-2020-21-single-stage In this project, a multinational consortium of high-tech SMEs, academic research institutes, biotech and pharma partners, affiliated patient...
2020-10-22 - 2024-03-31 | Financiado
imSAVAR: Immune Safety Avatar nonclinical mimicking of the immune system effects of immunomodulatory therapi... BIOSCI CONSULTING BVBA participó en un H2020 H2020-JTI-IMI2-2018-15-two-stage The vision of Immune Safety Avatar (imSAVAR) is to develop a platform for integrated nonclinical assessments of immunomodulatory therapy saf...
2019-11-18 - 2025-11-30 | Financiado
AIMS-2-TRIALS: Autism Innovative Medicine Studies 2 Trials BIOSCI CONSULTING BVBA participó en un H2020 H2020-JTI-IMI2-2016-10-two-stage Autism Spectrum Disorder (ASD) is a heterogeneous neurodevelopmental condition affecting over five million people in the European Union. Th...
2018-06-22 - 2025-05-31 | Financiado
ETRIKS: Delivering European Translational Information & Knowledge Management Services BIOSCI CONSULTING BVBA participó en un FP6 Since its inception the IMI has funded over 30 public-private partnership projects. Many of these projects are centered upon data intensive...
2012-10-01 - 2018-09-30 | Financiado
U-BIOPRED: Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes BIOSCI CONSULTING BVBA participó en un FP6 RationaleThe inability of pre-clinical studies to predict clinical efficacy is a major bottleneck in drug development. In severe asthma this...
2009-10-01 - 2015-09-30 | Financiado
AirPROM: Airway Disease PRedicting Outcomes through Patient Specific Computational Modelling BIOSCI CONSULTING BVBA participó en un FP7 The airways diseases asthma and chronic obstructive pulmonary disease affect over 400 million people world-wide and cause considerable morbi...
Financiado
U-BIOPRED: Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes BIOSCI CONSULTING BVBA participó en un FP7 Rationale The inability of pre-clinical studies to predict clinical efficacy is a major bottleneck in drug development. In severe asthma thi...
Financiado
ETRIKS: Delivering European Translational Information Knowledge Management Services BIOSCI CONSULTING BVBA participó en un FP7 Since its inception the IMI has funded over 30 public-private partnership projects. Many of these projects are centered upon data intensive...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.